Blood products giant CSL has received all regulatory clearances for its major $US11.7 billion ($16.7 billion) acquisition of Switzerland’s Vifor Pharma, paving the way for the ASX-listed biotech to enter into new territory with iron deficiency and kidney products.
It is welcome news for CSL management and investors, after the closing date for the deal was pushed out by several months while regulators sought more information.
Loading...
Yolanda Redrup is the co-editor of the AFR Rich List. She previously reported on technology, healthcare and Street Talk. Connect with Yolanda on Twitter. Email Yolanda at yolanda.redrup@afr.com
